TCGA-OR-A5LE-01
Adrenocortical Carcinoma · Adrenocortical Carcinoma · Adrenocortical Carcinoma, Usual Type
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.493
- E2F_TARGETS+0.486
- MYC_TARGETS_V1+0.448
- PANCREAS_BETA_CELLS+0.395
- MTORC1_SIGNALING+0.328
- MYC_TARGETS_V2+0.320
- OXIDATIVE_PHOSPHORYLATION+0.301
- CHOLESTEROL_HOMEOSTASIS+0.296
- PEROXISOME+0.289
- SPERMATOGENESIS+0.270
Top 10 suppressed
- IL6_JAK_STAT3_SIGNALING-0.511
- ALLOGRAFT_REJECTION-0.440
- INFLAMMATORY_RESPONSE-0.408
- INTERFERON_GAMMA_RESPONSE-0.386
- INTERFERON_ALPHA_RESPONSE-0.356
- IL2_STAT5_SIGNALING-0.348
- TNFA_SIGNALING_VIA_NFKB-0.329
- KRAS_SIGNALING_UP-0.268
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.265
- COMPLEMENT-0.263
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_052PZFMK | high-grade glioma | — | 0.908 |
| 2 | ec51dd1b-5733-485c-a09a-8d50d1d9fda1 | — | — | 0.896 |
| 3 | DRR168591 | — | — | 0.894 |
| 4 | MDT-AP-2956 | Med | Medulloblastoma | 0.892 |
| 5 | TCGA-66-2754-01A-01R-0980-07 | — | cohortA3 | 0.889 |
| 6 | AUR-AFR3-TTM1-A-1-1-R-A743-41 | — | C | 0.887 |
| 7 | TCGA-33-4582-01A-01R-1443-07 | — | cohortSQ2 | 0.886 |
| 8 | 236350e9-8964-42ae-8880-d2f2281ff993 | — | — | 0.881 |
| 9 | 20120209.TNBC | — | E | 0.880 |
| 10 | MNG1195 | — | — | 0.879 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.493 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.486 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.448 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.395 | Cobimetinib | — uncovered |
| MTORC1_SIGNALING | 0.328 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.320 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.301 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.296 | Remibrutinib | — uncovered |
| PEROXISOME | 0.289 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.270 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.240 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.208 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.204 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.159 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.138 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.126 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.118 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.105 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.060 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.011 | Inavolisib | — uncovered |